Eleanor N. Dana Cancer Center

/centers/cancer/
/centers/cancer/

Services

/  

Contact Us

Clinical trials at the Eleanor N. Dana Cancer Center

Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.


All Cancer Indications

Molecular Target Registry

+ More Info


Blood Cancers

Phase 1/2a Study of ZX-101A in CLL, SLL, and NHL

Mechanism: PI3K Inhibitor

+ More Info


Breast Cancer

Phase I study of KN026 in HER2 cancer

Mechanism:  Anti-HER2 bispecific antibody to non overlapping HER2 epitopes

+ More Info


Glioblastoma

Phase II of OKN-007 and TMZ in Recurrent Glioblastoma

Mechanism:  small molecule that targets heparin sulfate proteoglycans (HSPGs), can increase glioma tumor cell apoptosis and decrease proliferation and angiogenesis. It also increases vascular permeability, allowing drugs like temozolomide (TMZ) to accumulate in brain tissue.

+ More Info


Lung Cancer

Phase 1 Study of NBF-006 in Advanced Solid Tumor

Mechanism:  siRNA targeting Glutathione S-transferase P (GSTP) which modulates ras signaling.  Control of GSTP will inhibit ras signaling as related to cancer growth.  Most relevant to ras mutant positive tumors.

+ More Info

Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy (KICKSTART)

Mechanism: Highly selective kinase inhibitor for MNK1 and MNK2

+ More Info


Pancreatic Cancer

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info

Phase 3 of Relacorilant and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma

Mechanism:  Small molecule antagonist of the glucocorticoid receptor

+ More Info

Solid Tumor

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects with Selected Advanced Solid Tumor Malignancies

Mechanism:  eIF4E mRNA inhibitor

+ More Info

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info

Phase 1/1b of TTX-030 with Budigalimab and /or Chemo in Advanced Solid Tumors

Mechanism:  TTX-030 is a monoclonal antibody that inhibits protein CD39.

Budigalimab (ABBV-181) is a monoclonal antibody targeting PD-1.

+ More Info

Phase 2 of DPX-Survivac in combination with Cyclophosphamide and Pembrolizumab in Select Advanced and Recurrent Solid Tumors

Mechanism: DPX is a lipid-based “no release” formulation developed to specifically enhance immune responses by delivery to antigen presenting cells.

+ More Info


Urothelial (Renal pelvis, Ureter, and Bladder Cancers)

Phase 3 of FGFR3 Inhibitor vs Placebo in Invasive Urothelial Carcinoma

Mechanism:  FGFR3 target

+ More Info

Phase 3 of CG0070 in Non-Muscule Invasive Bladder Cancer (NMIBC) unresponsive to BCG

Mechanism:  Biological, Engineered Oncolytic Adenovirus

+ More Info


For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Stephanie Smiddy at 419.383.6962
/
Last Updated: 5/13/21